


## Data Sheet

<b>Product Name:</b>	MM-102 (TFA)
<b>Cat. No.:</b>	CS-5186
<b>CAS No.:</b>	1883545-52-5
<b>Molecular Formula:</b>	C37H50F5N7O6
<b>Molecular Weight:</b>	783.83
<b>Target:</b>	Histone Methyltransferase
<b>Pathway:</b>	Epigenetics
<b>Solubility:</b>	DMSO : $\geq 100$ mg/mL (127.58 mM)



### BIOLOGICAL ACTIVITY:

MM-102 TFA (HMTase Inhibitor IX TFA) is a potent WDR5/MLL interaction inhibitor, achieves  $IC_{50} = 2.4$  nM with an estimated  $K_i < 1$  nM in WDR5 binding assay, which is  $>200$  times more potent than the ARA peptide.  $IC_{50}$  & Target:  $IC_{50}$ : 2.4 nM (MLL)<sup>[1]</sup>. **In Vitro:** MM-102 (HMTase Inhibitor IX) inhibits MLL1 methyltransferase activity and MLL-1-induced HoxA9 and Meis-1 gene expression in leukemia cells expressing the MLL1-AF9 fusion gene. Also inhibits cell growth and induces apoptosis in leukemia cells harbouring MLL1 fusion proteins.

MM-102 (TFA), with the highest binding affinities to WDR5, also show the most potent inhibitory activity in the HMT assay with  $IC_{50} = 0.4$ - $0.9$   $\mu$ M<sup>[1]</sup>.

MM-102 (HMTase Inhibitor IX) dose-dependently inhibits cell growth in the MV4;11 and KOPN8 leukemia cell lines, which carry MLL1-AF4 and MLL1-ENL fusion proteins, respectively<sup>[1]</sup>.

MM-102 (HMTase Inhibitor IX) has  $IC_{50} = 25$   $\mu$ M in both cell lines and completely inhibits cell growth in these cell lines at 75  $\mu$ M<sup>[1]</sup>.

MM-102 (HMTase Inhibitor IX) effectively and selectively inhibits cell growth and induces apoptosis in leukemia cells harboring MLL1 fusion proteins and has minimal effect in leukemia cells with wild-type MLL1 protein<sup>[1]</sup>.

### PROTOCOL (Extracted from published papers and Only for reference)

**Cell Assay:** MV4;11, KOPN8, and K562 cells were cultured in RPMI 1640 medium (ATCC) supplemented with 10% fetal bovine serum and 100 U/L penicillin/streptomycin and incubated at 37°C under 5% CO<sub>2</sub>. Cells were seeded into 12-well plates for suspension at a density of  $5 \times 10^5$  per well (1 mL) and treated with either vehicle control (DMSO, 0.2%) or MM-102 (HMTase Inhibitor IX) for 7 days. The medium was changed every 2 days, and compounds were resupplied. The CellTiter-Glo Luminescent Cell Viability Assay kit was used. First, 100  $\mu$ L of the assay reagent was added into each well, and the content was mixed for 2 min on an orbital shaker to induce cell lysis. After 10 min incubation at room temperature, the luminescence was read on a microplate reader.

### References:

[1]. Karatas H, et al. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. J Am Chem Soc. 2013 Jan 16;135(2):669-682.

### CAIndexNames:

(S)-N-(bis(4-fluorophenyl)methyl)-1-(2-(2-ethyl-2-isobutyramidobutanamido)-5-guanidinopentanamido)cyclopentanecarboxamide 2,2,2-trifluoroacetate

### SMILES:

O=C(C1(NC([C@@H](NC(C(NC(C(C)C)=O)(CC)CC)=O)CCCNC(N)=N)=O)CCCC1)NC(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3.FC(F)(F)C(O)=O

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA